4P-Pharma News - LARVOL Sigma

|||||||||| Victoza (liraglutide) / Novo Nordisk, liraglutide (4P004) - 4P / Pharma
Beyond Pain and Inflammation: Intra-articular Liraglutide's Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2036;
LIRA demonstrates greater potency compared to DEX in preserving synovial tissue and cartilage integrity. This underscores LIRA's potential as a superior treatment option for OA, addressing both symptomatic relief and structural preservation.

||||||||||  liraglutide (4P004) - 4P / Pharma
Trial completion, Trial completion date, Trial primary completion date:  LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) -  Jan 1, 2024
P1, N=34, Completed,  Sponsor: 4Moving Biotech
This underscores LIRA's potential as a superior treatment option for OA, addressing both symptomatic relief and structural preservation. Recruiting --> Completed | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023

||||||||||  liraglutide (4P004) - 4P / Pharma
Trial completion date, Trial primary completion date:  LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) -  Oct 25, 2022
P1, N=32, Recruiting,  Sponsor: 4Moving Biotech
Recruiting --> Completed | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023 Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023

|||||||||| Victoza (liraglutide) / Novo Nordisk, liraglutide (4P-004) - 4P / Pharma
Beneficial Structural Impact of Liraglutide, a GLP1 Receptor Agonist, in Three Inflammatory and Post-traumatic OA Animal Models (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1296;
Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep.

||||||||||  liraglutide (4P004) - 4P / Pharma
Enrollment open:  LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) -  Aug 12, 2022
P1, N=32, Recruiting,  Sponsor: 4Moving Biotech
Sci Rep. Not yet recruiting --> Recruiting



	Diseases Companies Products Productz Mechanisms of Action Sites